Certara Inc (CERT)

Currency in USD
10.62
+0.48(+4.73%)
Closed·
After Hours
10.620.00(0.00%)
·
CERT Scorecard
Full Analysis
Net income is expected to grow this year
Earnings results expected in 14 days
Fair Value
Day's Range
10.1810.80
52 wk Range
8.6416.18
Key Statistics
Prev. Close
10.62
Open
10.25
Day's Range
10.18-10.8
52 wk Range
8.64-16.18
Volume
1.91M
Average Volume (3m)
1.84M
1-Year Change
-35.95%
Book Value / Share
6.73
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CERT Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
15.22
Upside
+43.34%
Members' Sentiments
Bearish
Bullish
ProTips
Liquid assets exceed short term obligations

Certara Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Certara Inc Company Profile

Certara, Inc., together with its subsidiaries, provides technology-enabled services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes. The company also provides Phoenix WinNonlin, a platform for non-compartmental analysis; Phoenix Hosted, which offers a secured and validated Certara Amazon Web Services workspace; Phoenix NLME, a population modeling and simulation software; and Pirana Modeling Workbench, which provides modelers with a structure to facilitate the iterative processes. In addition, it offers Chemaxon JChem engines, a chemical search engine; Chemaxon Compound Registration, which supports a streamlined lead optimization process workflow; Chemaxon Design Hub, a design and tracking platform for drug discovery teams and their external collaborators; Certara D360 software, a scientific informatics system for small molecule and biologics discovery research; and Chemaxon Marvin, a chemical drawing tool. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange to define data standards and specifications; Metadata Repository that enables study design using controlled and standardized data; CoAuthor software, which creates and assembles regulatory submissions and medical publications; and GlobalSubmit, a submissions management software. Certara Inc. was founded in 2008 and is headquartered in Radnor, Pennsylvania.

Employees
1517

Certara Inc SWOT Analysis


AI-Driven Growth
Explore Certara's strategic investments in artificial intelligence and new software releases, positioning the company at the forefront of biosimulation innovation
Cloud Platform Vision
Delve into Certara's ambitious development of a comprehensive Cloud platform, aiming to revolutionize clinical trial software integration and efficiency
Market Challenges
Uncover the complexities Certara faces in its regulatory services segment and the impact on overall growth projections, with analysts targeting $12.00
Financial Landscape
Examine Certara's financial performance, including a 14% revenue increase and healthy gross profit margins, amid a cautious market outlook
Read full SWOT analysis

Certara Inc Earnings Call Summary for Q1/2025

  • Q1 2025 EPS of $0.14 beat forecast by 27%; revenue grew 10% YoY to $106M, driven by software and services growth
  • Company announced $100M share repurchase program; stock rose 0.31% in after-hours trading
  • Full-year 2025 revenue projected at $415-425M (8-10% growth); adjusted EBITDA margin of 30-32% expected
  • Strategic focus on AI integration and expansion into earlier drug development stages
  • Risks include regulatory changes, biotech funding challenges, and economic uncertainties affecting pharma spending
Last Updated: 05/05/2025, 23:02
Read Full Transcript

Compare CERT to Peers and Sector

Metrics to compare
CERT
Peers
Sector
Relationship
P/E Ratio
−656.4x−1.2x−0.5x
PEG Ratio
−6.61−0.010.00
Price/Book
1.6x1.0x2.6x
Price / LTM Sales
4.4x1.7x3.2x
Upside (Analyst Target)
47.9%13.1%42.7%
Fair Value Upside
Unlock10.7%5.8%Unlock

Analyst Ratings

5 Buy
6 Hold
0 Sell
Ratings:
11 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 15.22
(+43.34% Upside)

Earnings

Latest Release
May 05, 2025
EPS / Forecast
0.14 / 0.11
Revenue / Forecast
106.00M / 104.84M
EPS Revisions
Last 90 days

CERT Income Statement

People Also Watch

14.63
DXC
+1.95%
121.17
PHM
+11.52%
357.25
CMI
+3.66%
44.440
SMR
-2.20%
105.69
DECK
+0.56%

FAQ

What Stock Exchange Does Certara Trade On?

Certara is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Certara?

The stock symbol for Certara is "CERT."

What Is the Certara Market Cap?

As of today, Certara market cap is 1.72B.

What Is Certara's Earnings Per Share (TTM)?

The Certara EPS (TTM) is -0.02.

When Is the Next Certara Earnings Date?

Certara will release its next earnings report on 05 Aug 2025.

From a Technical Analysis Perspective, Is CERT a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Certara Stock Split?

Certara has split 0 times.

How Many Employees Does Certara Have?

Certara has 1517 employees.

What is the current trading status of Certara (CERT)?

As of 23 Jul 2025, Certara (CERT) is trading at a price of 10.62, with a previous close of 10.62. The stock has fluctuated within a day range of 10.18 to 10.80, while its 52-week range spans from 8.64 to 16.18.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.